This report is no longer available. Click here to view our current reports or contact us to discuss a custom report.

If you have previously purchased this report then please use the download links on the right to download the files.

2025年-2035年糖尿病管理技术：市场、参与者和预测

电化学葡萄糖检测试纸、持续性葡萄糖监测仪（CGM）、胰岛素泵、胰岛素笔和混合闭环人工胰腺。2010年-2035年糖尿病管理设备市场分析与预测。

显示全部 说明 内容、图表列表 常见问题解答 价格 Related Content
本报告涵盖了糖尿病管理市场主要医疗器械领域的技术革新和市场动态，包括持续性血糖监测、胰岛素泵和先进的混合闭环胰岛素管理系统。报告中还讨论了非侵入性葡萄糖监测技术、非侵入性胰岛素输送手段和新型疗法等替代技术的进展。该报告还包括2010年起的历史数据和展望至2035年的十年市场预测。
技术分析：
  • 血糖感应机制
  • 电化学测试条材料及制造
  • 商业化连续血糖监测仪的关键指标，包括准确性
  • 无创血糖技术的基准测试
  • 商业化胰岛素泵和先进的混合闭环软件的关键指标
  • 替代胰岛素技术概述
  • 糖尿病并发症检测与诊断技术概述
 
主要参与者、产品及收入分析：
  • 自我监测血糖
  • 连续血糖监测
  • 胰岛素泵
 
市场预测：
  • 2025-2035年自我监测血糖、连续血糖监测、胰岛素笔、有线胰岛素泵、胰岛素贴片泵的10年市场预测
  • 所有细分市场自2014年以来的历史市场数据，部分细分市场自2010年以来的数据
 
1. 执行摘要与结论
2. 引言
2.1 主要糖尿病管理参与者介绍
3. 血糖传感器
3.1 血糖传感器介绍
3.2 自我监测血糖：血糖测试条
3.3 自我监测血糖：市场与主要参与者
3.4 连续血糖监测（CGM）
3.5 连续血糖监测：市场与主要参与者
3.6 无创血糖监测技术
4. 胰岛素输送
4.1 胰岛素输送介绍
4.2 胰岛素笔
4.3 胰岛素泵
4.4 胰岛素泵：市场与主要参与者
4.5 替代胰岛素技术
5. 向闭环系统和人工胰腺发展
6. 数字健康
7. 糖尿病的先进疗法
8. 糖尿病并发症技术
8.1 介绍
8.2 糖尿病酮症酸中毒
8.3 糖尿病神经病变和视网膜病变
9. 市场预测
10. 公司简介
 
This IDTechEx report on diabetes management technologies and markets covers the entire landscape of medical devices, including mature, emerging and future options. The report discusses key technologies and companies in electrochemical glucose test strips, continuous glucose monitoring, insulin pens, insulin pumps, automated insulin delivery. Progress in emerging technologies such as non-invasive glucose monitoring is also discussed in the report. This IDTechEx report contains historical market data and ten-year market forecasts across four key product categories to 2035.
 
The diabetes management device market has seen major changes over the past decade. At the center is the shift from electrochemical glucose test strips that require fingers to be pricked towards minimally invasive continuous glucose monitors (CGMs). The multibillion-dollar test strip industry has been in steady decline since the 2010s while the CGM companies have experienced consistent growth. IDTechEx predicts that by 2035, annual revenues from glucose test strips will only make up 5.15% of the total market for diabetes management devices.
 
Annual revenue for continuous glucose monitoring (CGM) has overtaken that of self-monitoring blood glucose (including glucose test strips).
 
Glucose sensors: Past, present, and future
People with diabetes have historically used glucose test strips to monitor their blood glucose levels. The glucose testing market was valued at over US$7.8 billion in 2010, and was based on a high margin, razor blade business model. However, a combination of pricing pressures, more stringent reimbursement policies, and the shift of users to CGMs have been driving the decline of the test strip industry. Combined, these factors have resulted in former blood glucose testing market leaders divesting their diabetes divisions, and a shift of market share to players in East Asia.
 
On the other hand, the CGM market has seen rapid growth over the past decade. IDTechEx estimates a CAGR of 30% between 2015 and 2025. The shift from discrete to continuous monitoring is expected to continue over the next ten years, including expanding reimbursement around the world to include people with type 2 diabetes. In this report we discuss the outlook for both the glucose test strip market and CGM market going forward, along with ten-year market forecasts.
 
Insulin delivery: Progress towards closing the loop
Insulin delivery is the other half of the diabetes management market. Currently, for most people with diabetes, insulin is delivered using insulin pens. Over the next ten years, IDTechEx expects more people to shift from using insulin pens towards insulin pump therapy. Key drivers of this include new insulin pumps coming to market, new form factors such as the insulin patch pump, and the advancement of insulin delivery algorithms (and integration with CGMs). The further development of insulin delivery algorithms, and automated insulin delivery (AID) systems, will be key to the insulin pump market.
The market for insulin pumps in 2023 is led by Insulet and Medtronic.
 
Digital health: Expansion of CGM into type 2 diabetes
Digital health plays a central role in diabetes management. Today, the advancement of connected medical devices such as CGMs, insulin pumps, and connected glucometers and smart insulin pens are enabling a wealth of data to be analyzed and shared online. In addition to easing some of the burden of diabetes management, digital health can provide context and education to people with diabetes. For example, a connected insulin pen, when combined with a CGM, can help users see the impact of each insulin dose on their blood glucose. Similarly, the expansion of CGMs into the consumer, prediabetes and type 2 diabetes markets will provide insight into how user's food and lifestyle choices impact their blood glucose levels.
 
Diabetes management device market analysis and forecasts
The glucose sensing and insulin delivery industries are highly interlinked - developments within one industry cause significant effects on others. IDTechEx have analyzed the entire market to produce a cohesive story, tying together developments and future milestones across the diabetes management industry to provide a realistic forecast of each individual market.
 
This report analyzes the technological and competitive landscapes of diabetes management, identifying and reviewing over 100 companies ranging from industry leaders to startups. It identifies key players in each sector along with partnerships across several industries.
Report MetricsDetails
Historic Data2010 - 2024
CAGRThe global market for diabetes management technologies will grow at CAGR 5.21% from 2025-2035
Forecast Period2025 - 2035
Forecast UnitsRevenue (US$ billions)
Regions CoveredWorldwide
Segments CoveredSelf monitoring blood glucose (including glucose readers and electrochemical glucose test strips), continuous glucose monitors (CGM), insulin pumps, tethered insulin pumps, insulin patch pumps, insulin pens.
从 IDTechEx 访问分析师
所有报告购买订单均包括与一名专家分析师进行 30 分钟的电话交谈，专家分析师将帮助您将报告中的重要发现与您正在处理的业务问题联系起来。这需要在购买报告后的三个月内使用。
更多信息
如果您对这一报告有任何疑问，请随时联系我们的报告团队 research@IDTechEx.com 或致电我们的销售经理：

AMERICAS (USA): +1 617 577 7890
ASIA (Japan and Korea): +81 3 3216 7209
EUROPE (UK) +44 1223 812300
1.EXECUTIVE SUMMARY AND CONCLUSIONS
1.1.Executive introduction
1.2.Executive introduction
1.3.Introduction to diabetes
1.4.The cost of diabetes
1.5.Blood glucose management basics
1.6.Diabetes management device roadmap: Summary
1.7.Diabetes management device roadmap: Glucose sensors
1.8.Blood glucose monitoring test strips and associated readers
1.9.Continuous glucose monitoring
1.10.Focus shifts from glucose test strips to CGMs
1.11.When will non-invasive glucose monitoring be commercialized?
1.12.Diabetes management device roadmap: Insulin delivery
1.13.Insulin pens
1.14.Insulin pumps
1.15.Introduction to automated insulin delivery (AID) systems
1.16.Closing the loop will drive further insulin pump uptake
1.17.Digital health is at the core of diabetes management
1.18.Diabetes device industry market forecast 2025-2035
1.19.Diabetes device industry market forecast 2025-2035: Discussion
1.20.Access More With an IDTechEx Subscription
2.INTRODUCTION
2.1.1.Introduction to diabetes
2.1.2.Diabetes is on the rise
2.1.3.The cost of diabetes
2.1.4.Type 1 Diabetes vs Type 2 Diabetes
2.1.5.Blood glucose levels: Hyperglycemia and hypoglycemia
2.1.6.Medical devices for diabetes self management
2.1.7.Diabetes management device roadmap: Summary
2.1.8.Diabetes management device roadmap: Glucose sensors
2.1.9.Diabetes management device roadmap: Insulin delivery
2.2.Introduction to Key Diabetes Management Players
2.2.1.Key diabetes management companies covered in this report
2.2.2.Roche Diabetes Care
2.2.3.Abbott Diabetes Care
2.2.4.Dexcom
2.2.5.Medtronic Diabetes Operating Unit
2.2.6.Novo Nordisk Diabetes Care
2.2.7.Insulet
3.GLUCOSE SENSORS
3.1.Introduction to Glucose Sensors
3.1.1.History of glucose monitoring
3.1.2.History of glucose monitoring
3.1.3.Glucose monitoring: Key players
3.1.4.Diabetes management device roadmap: Glucose sensors
3.1.5.Key criteria for assessing accuracy
3.1.6.Glucose oxidase: Introduction
3.1.7.Glucose oxidase: Mechanism
3.1.8.Glucose dehydrogenase: Introduction
3.1.9.Glucose dehydrogenase: Mechanism and mediators
3.1.10.Glucose dehydrogenase vs glucose oxidase
3.1.11.Glucose dehydrogenase vs glucose oxidase: Advantages and disadvantages
3.1.12.The generations of glucose sensors
3.1.13.The generations of glucose sensors
3.1.14.The generations of glucose sensors: Advantages and disadvantages
3.2.Self-Monitoring Blood Glucose: Glucose Test Strips
3.2.1.Blood glucose monitoring test strips and associated readers
3.2.2.Anatomy of a glucose test strip
3.2.3.Electrode deposition: Screen printing vs sputtering
3.2.4.Companies utilize multiple manufacturing methods
3.2.5.Innovation shifts from test strip development to increasing digitalization
3.3.Self-Monitoring Blood Glucose: Market and Key Players
3.3.1.Blood glucose monitoring: Business model
3.3.2.Blood glucose monitoring: Market share
3.3.3.Roche Diabetes Care: Accu-Chek
3.3.4.Roche Diabetes Care: SMBG revenue
3.3.5.Abbott Diabetes Care: FreeStyle Optium
3.3.6.LifeScan: OneTouch
3.3.7.Challenges to the blood glucose monitoring market
3.3.8.Cost of glucose test strips vs continuous glucose monitors
3.3.9.Glucose test strips: Market outlook
3.4.Continuous Glucose Monitoring (CGM)
3.4.1.Continuous glucose monitoring
3.4.2.Benefits of continuous glucose monitoring
3.4.3.Anatomy of a typical CGM device
3.4.4.CGM technology
3.4.5.CGM sensor chemistry: Abbott, Dexcom, Medtronic
3.4.6.CGM sensor chemistry: Fluorescence-based glucose sensing
3.4.7.CGM sensor anatomy and manufacturing
3.4.8.CGM sensor filament structure
3.4.9.Implantable glucose sensors
3.4.10.Foreign body response to CGM devices
3.4.11.CGMs move to factory calibration
3.4.12.Comparison of recently launched CGM devices
3.4.13.Accuracy of CGM devices over time
3.4.14.Interference of medication with CGM accuracy
3.4.15.Predictive glucose and the potential for artificial intelligence
3.5.Continuous Glucose Monitoring: Market and Key Players
3.5.1.Focus shifts from glucose test strips to CGMs
3.5.2.CGM: overview of key players
3.5.3.Abbott Diabetes Care: FreeStyle Libre
3.5.4.Abbott Diabetes Care: Wired enzyme technology
3.5.5.Abbott Diabetes Care: Sensor structure
3.5.6.Dexcom: G6 & G7
3.5.7.Dexcom: ONE, ONE+, Stelo
3.5.8.Senseonics: Eversense
3.5.9.Senseonics: Sensor technology
3.5.10.Implantable CGMs
3.5.11.Reimbursement of CGM technologies grows
3.5.12.CGM markets in Asia
3.5.13.New entrants in the CGM market
3.5.14.Clinician concern for CGMs in type 2 diabetes
3.5.15.Reimbursement for type 2 diabetes is currently limited
3.5.16.Direct to consumer CGMs for T2D and wellness
3.5.17.CGM in hospitals
3.5.18.CGM: market outlook
3.6.Non-Invasive Glucose Monitoring Technology
3.6.1.Non-invasive glucose monitoring
3.6.2.In context: FDA requirements for blood glucose monitoring
3.6.3.FDA safety communication on non-invasive smart watches
3.6.4.Non-invasive techniques for blood and interstitial glucose
3.6.5.Summary of non-invasive glucose sensing techniques
3.6.6.Near-infrared (NIR) and short-wave infrared (SWIR) spectroscopy
3.6.7.Mid-infrared spectroscopy
3.6.8.Raman spectroscopy
3.6.9.Optical rotation
3.6.10.Dielectric spectroscopy
3.6.11.Transdermal techniques
3.6.12.Reverse iontophoresis
3.6.13.Assessment of different analytes for non-invasive glucose monitoring
3.6.14.Measuring glucose in sweat
3.6.15.Measuring glucose in tears
3.6.16.Measuring glucose in saliva
3.6.17.Measuring glucose in breath
3.6.18.Measuring glucose in urine
3.6.19.When will non-invasive glucose monitoring be commercialized?
3.6.20.Non-invasive glucose sensing techniques: Company landscape
4.INSULIN DELIVERY
4.1.Introduction to Insulin Delivery
4.1.1.Insulin
4.1.2.Delivering insulin is a critical part of diabetes management
4.1.3.Types of insulin and their use cases
4.1.4.Comparison of different types of insulin
4.1.5.Short-acting (bolus) insulin
4.1.6.Long-acting (basal) insulin
4.1.7.Diabetes management device roadmap: Insulin delivery
4.2.Insulin Pens
4.2.1.Insulin pens
4.2.2.Smarter insulin delivery informing decisions
4.2.3.Smart insulin pen: Essential functions
4.2.4.Growing digital health market drives smart pen uptake
4.2.5.Overview of commercial smart pen devices
4.2.6.Novo Nordisk: FlexPen, FlexTouch, NovoPen 6, & NovoPen Echo Plus
4.2.7.Outlook for insulin pens
4.3.Insulin Pumps
4.3.1.Insulin pumps
4.3.2.Insulin patch pumps
4.3.3.Insulin pump breakdown
4.3.4.Overview of commercial insulin pumps
4.3.5.Barriers to insulin pump adoption
4.3.6.Device security: Implications for insulin pumps
4.4.Insulin Pumps: Market and Key Players
4.4.1.Insulin pump market
4.4.2.Insulin pump market: Overview of key players
4.4.3.Technology innovations drive insulin pump market
4.4.4.The rise of the tubeless insulin pumps
4.4.5.Pricing models for patch pumps vs tethered pumps
4.4.6.Medtronic: MiniMed 780G
4.4.7.Insulet: Omnipod 5
4.4.8.Insulet: Omnipod DASH, Omnipod GO
4.4.9.Insulin pumps: Market outlook
4.5.Alternative Insulin Technologies
4.5.1.Non-invasive insulin delivery methods
4.5.2.Assessment of different routes for non-invasive insulin delivery
4.5.3.Inhaled insulin: Introduction
4.5.4.Inhaled insulin: Commercial challenges
4.5.5.Oral insulin
4.5.6.Buccal insulin
4.5.7.Transdermal insulin
4.5.8.Non-invasive insulin: Barriers to market adoption
4.5.9.Glucose-responsive insulin
4.5.10.The poor track record in non-invasive insulin
5.TOWARDS CLOSED-LOOP SYSTEMS AND ARTIFICIAL PANCREAS
5.1.Introduction to automated insulin delivery (AID) systems
5.2.Insulin pump technology roadmap
5.3.Interoperability essential to new hybrid closed-loop systems
5.4.Advanced hybrid closed-loop
5.5.Model predictive control
5.6.PID control
5.7.Case study: Progress from Medtronic
5.8.Medtronic: SmartGuard and Meal Detection
5.9.Medtronic: SmartGuard and Meal Detection
5.10.Dexcom: Partnerships for hybrid-closed loop systems
5.11.Interoperable automated glycemic controllers (iAGCs)
5.12.Progress towards automated insulin delivery
6.DIGITAL HEALTH
6.1.Diabetes is an early adopter of digital healthcare initiatives
6.2.Diabetes digital health landscape
6.3.Diabetes management apps: Ecosystem
6.4.Diabetes management apps
6.5.Digital health and connected diabetes management hardware
6.6.CGM integration with mobile apps
6.7.Lifestyle management apps: Focal points
6.8.Diet management: Meal tracking and diet planning
6.9.Telehealth in diabetes: Introduction
6.10.Regulatory requirements: Telemedicine
6.11.Telehealth in Type 2 and pre-diabetes: Examples
6.12.Addressing prediabetes via digital health
6.13.Digital health programs: Evidence for type 2 diabetes
6.14.Digital health and diabetes: Outlook
7.ADVANCED THERAPIES FOR DIABETES
7.1.Diabetes management device roadmap: Advanced therapies
7.2.Advanced therapies: Introduction
7.3.Cell therapy devices for type 1 diabetes
7.4.Advanced therapies: Conclusions
8.TECHNOLOGIES FOR DIABETES COMPLICATIONS
8.1.Introduction
8.1.1.Managing side effects accounts for 90% of the total cost of diabetes
8.2.Diabetic Ketoacidosis
8.2.1.Diabetic ketoacidosis: Introduction
8.2.2.Ketone monitoring: Electrochemical sensors
8.2.3.Ketone monitoring: Urine test strips
8.2.4.Ketone monitoring: Outlook
8.2.5.Diabetic Neuropathy & Retinopathy
8.2.6.Diabetic neuropathy and diabetic foot ulcers
8.2.7.Diabetic foot ulcers: Smart footwear for monitoring
8.2.8.Diabetic retinopathy: Introduction
8.2.9.Diabetic retinopathy: AI image recognition software
8.2.10.Diabetic retinopathy: Wearable vision aids
8.2.11.Diabetic neuropathy and retinopathy: Outlook
9.MARKET FORECASTS
9.1.Introduction
9.2.Market sizing and forecast methodology
9.3.Diabetes device industry market forecast 2025-2035
9.4.Diabetes device industry market forecast by proportion 2025-2035
9.5.Diabetes device industry market forecast 2025-2035: Discussion
9.6.Self monitoring blood glucose market forecast 2025-2035
9.7.Self monitoring blood glucose market forecast 2025-2035: Discussion
9.8.CGM market forecast 2025-2035
9.9.CGM market forecast 2025-2035: Discussion
9.10.Insulin pen market forecast 2025-2035
9.11.Insulin pump market forecast 2025-2035
9.12.Insulin pump market forecast 2025-2035: Discussion
9.13.Tethered insulin pump market forecast 2025-2035
9.14.Insulin patch pump market forecast 2025-2035
10.COMPANY PROFILES
10.1.Abbott Diabetes Care
10.2.Abbott Diabetes Care update
10.3.AgaMatrix
10.4.Alpha Pharma
10.5.Artelus
10.6.Beta Bionics
10.7.Bionime
10.8.CamDiab
10.9.Carbometrics
10.10.CNOGA Medical
10.11.Dexcom
10.12.Dexcom update
10.13.DiabeLoop
10.14.Diabeloop update
10.15.DiaMonTech
10.16.Digital Diagnostics (formerly known as IDx)
10.17.Fitscript
10.18.Glooko
10.19.Glooko update
10.20.GlucoRx
10.21.GlucoRx (BioXensor)
10.22.i-Sens
10.23.Impeto Medical
10.24.Infinovo
10.25.Inreda Diabetic
10.26.Insulet
10.27.Kriya Therapeutics
10.28.MannKind
10.29.Medtronic (Diabetes Division)
10.30.Medtronic Diabetes
10.31.Medtrum Technologies
10.32.National Diagnostic Products
10.33.Nemaura Medical
10.34.Orpyx
10.35.PKvitality
10.36.PKVitality update
10.37.Quantum Operation
10.38.RSP Systems
10.39.RSP Systems update
10.40.Senseonics
10.41.Siren Care Denmark
10.42.SNAQ
10.43.SOOIL Development
10.44.TaiDoc
10.45.Tidepool
10.46.Welldoc: Diabetes
 

About IDTechEx reports

What are the qualifications of the people conducting IDTechEx research?

Content produced by IDTechEx is researched and written by our technical analysts, each with a PhD or master's degree in their specialist field, and all of whom are employees. All our analysts are well-connected in their fields, intensively covering their sectors, revealing hard-to-find information you can trust.

How does IDTechEx gather data for its reports?

By directly interviewing and profiling companies across the supply chain. IDTechEx analysts interview companies by engaging directly with senior management and technology development executives across the supply chain, leading to revealing insights that may otherwise be inaccessible.
 
Further, as a global team, we travel extensively to industry events and companies to conduct in-depth, face-to-face interviews. We also engage with industry associations and follow public company filings as secondary sources. We conduct patent analysis and track regulatory changes and incentives. We consistently build on our decades-long research of emerging technologies.
 
We assess emerging technologies against existing solutions, evaluate market demand and provide data-driven forecasts based on our models. This provides a clear, unbiased outlook on the future of each technology or industry that we cover.

What is your forecast methodology?

We take into account the following information and data points where relevant to create our forecasts:
  • Historic data, based on our own databases of products, companies' sales data, information from associations, company reports and validation of our prior market figures with companies in the industry.
  • Current and announced manufacturing capacities
  • Company production targets
  • Direct input from companies as we interview them as to their growth expectations, moderated by our analysts
  • Planned or active government incentives and regulations
  • Assessment of the capabilities and price of the technology based on our benchmarking over the forecast period, versus that of competitive solutions
  • Teardown data (e.g. to assess volume of materials used)
  • From a top-down view: the total addressable market
  • Forecasts can be based on an s-curve methodology where appropriate, taking into account the above factors
  • Key assumptions and discussion of what can impact the forecast are covered in the report.

How can I be confident about the quality of work in IDTechEx reports?

Based on our technical analysts and their research methodology, for over 25 years our work has regularly received superb feedback from our global clients. Our research business has grown year-on-year.
 
Recent customer feedback includes:
"It's my first go-to platform"
- Dr. Didi Xu, Head of Foresight - Future Technologies, Freudenberg Technology Innovation
 
"Their expertise allows us to make data-driven, strategic decisions and ensures we remain aligned with the latest trends and opportunities in the market."
- Ralf Hug, Global Head of Product Management & Marketing, Marquardt

What differentiates IDTechEx reports?

Our team of in-house technical analysts immerse themselves in industries over many years, building deep expertise and engaging directly with key industry players to uncover hard-to-find insights. We appraise technologies in the landscape of competitive solutions and then assess their market demand based on voice-of-the-customer feedback, all from an impartial point of view. This approach delivers exceptional value to our customers—providing high-quality independent content while saving customers time, resources, and money.

Why should we pick IDTechEx research over AI research?

A crucial value of IDTechEx research is that it provides information, assessments and forecasts based on interviews with key people in the industry, assessed by technical experts. AI is trained only on content publicly available on the web, which may not be reliable, in depth, nor contain the latest insights based on the experience of those actively involved in a technology or industry, despite the confident prose.

How can I justify the ROI of this report?

Consider the cost of the IDTechEx report versus the time and resources required to gather the same quality of insights yourself. IDTechEx analysts have built up an extensive contact network over many years; we invest in attending key events and interviewing companies around the world; and our analysts are trained in appraising technologies and markets.
 
Each report provides an independent, expert-led technical and market appraisal, giving you access to actionable information immediately, rather than you having to spend months or years on your own market research.

Can I speak to analysts about the report content?

All report purchases include up to 30 minutes of telephone time with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This needs to be used within three months of purchasing the report.

What is the difference between a report and subscription?

A subscription from IDTechEx can include more reports, access to an online information platform with continuously updated information from our analysts, and access to analysts directly.

Before purchasing, I have some questions about the report, can I speak to someone?

Please email research@idtechex.com stating your location and we will quickly respond.

About IDTechEx

Who are IDTechEx's customers?

IDTechEx has served over 35,000 customers globally. These range from large corporations to ambitious start-ups, and from Governments to research centers. Our customers use our work to make informed decisions and save time and resources.

Where is IDTechEx established?

IDTechEx was established in 1999, and is headquartered in Cambridge, UK. Since then, the company has significantly expanded and operates globally, having served customers in over 80 countries. Subsidiary companies are based in the USA, Germany and Japan.

Questions about purchasing a report

How do I pay?

In most locations reports can be purchased by credit card, or else by direct bank payment.

How and when do I receive access to IDTechEx reports?

When paying successfully by credit card, reports can be accessed immediately. For new customers, when paying by bank transfer, reports will usually be released when the payment is received. Report access will be notified by email.

How do I assign additional users to the report?

Users can be assigned in the report ordering process, or at a later time by email.

Can I speak to someone about purchasing a report?

Please email research@idtechex.com stating your location and we will quickly respond.
 
2035年，糖尿病管理技术市场（规模）将达440亿美元。

报告统计信息

幻灯片 246
预测 2035
 

Customer Testimonial

quote graphic
"The resources produced by IDTechEx are a valuable tool... Their insights and analyses provide a strong foundation for making informed, evidence-based decisions. By using their expertise, we are better positioned to align our strategies with emerging opportunities."
Director of Market Strategy
Centre for Process Innovation (CPI)
 
 
 
ISBN: 9781835700860

Subscription Enquiry